BR112022017574A2 - Compostos que têm como alvo proteínas de ligação ao rna ou proteínas modificadoras de rna - Google Patents

Compostos que têm como alvo proteínas de ligação ao rna ou proteínas modificadoras de rna

Info

Publication number
BR112022017574A2
BR112022017574A2 BR112022017574A BR112022017574A BR112022017574A2 BR 112022017574 A2 BR112022017574 A2 BR 112022017574A2 BR 112022017574 A BR112022017574 A BR 112022017574A BR 112022017574 A BR112022017574 A BR 112022017574A BR 112022017574 A2 BR112022017574 A2 BR 112022017574A2
Authority
BR
Brazil
Prior art keywords
rna
proteins
compounds
modifying
binding proteins
Prior art date
Application number
BR112022017574A
Other languages
English (en)
Inventor
M Ericsson Anna
Ghosh Shomir
Martin Harvey Darren
Original Assignee
Twentyeight Seven Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twentyeight Seven Inc filed Critical Twentyeight Seven Inc
Publication of BR112022017574A2 publication Critical patent/BR112022017574A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTOS QUE TÊM COMO ALVO PROTEÍNAS DE LIGAÇÃO AO RNA OU PROTEÍNAS MODIFICADORAS DE RNA. A presente invenção refere-se a um composto representado pela Fórmula (I): ou um sal farmaceuticamente aceitável do mesmo, composições que compreendem os mesmos e métodos de preparação e uso dos mesmos. As variáveis são descritas no presente documento.
BR112022017574A 2020-03-03 2021-03-02 Compostos que têm como alvo proteínas de ligação ao rna ou proteínas modificadoras de rna BR112022017574A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062984677P 2020-03-03 2020-03-03
PCT/US2021/020494 WO2021178420A1 (en) 2020-03-03 2021-03-02 Compounds targeting rna-binding proteins or rna-modifying proteins

Publications (1)

Publication Number Publication Date
BR112022017574A2 true BR112022017574A2 (pt) 2022-11-16

Family

ID=75223420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017574A BR112022017574A2 (pt) 2020-03-03 2021-03-02 Compostos que têm como alvo proteínas de ligação ao rna ou proteínas modificadoras de rna

Country Status (11)

Country Link
EP (1) EP4114831A1 (pt)
JP (1) JP2023517539A (pt)
KR (1) KR20230022829A (pt)
CN (1) CN116157392A (pt)
AU (1) AU2021231765A1 (pt)
BR (1) BR112022017574A2 (pt)
CA (1) CA3170415A1 (pt)
IL (1) IL296137A (pt)
MX (1) MX2022010957A (pt)
TW (1) TW202146398A (pt)
WO (1) WO2021178420A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023137325A (ja) * 2022-03-18 2023-09-29 日清食品ホールディングス株式会社 ２－アセチル－１－ピロリンの製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US756011A (en) 1903-06-01 1904-03-29 James L Fitz Gerald Gasolene-motor.
RU2139351C1 (ru) 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2017156557A1 (en) 2016-03-07 2017-09-14 Northeast Ohio Medical University Animal model for studying zcchc6 in bone disease and development
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2018005608A1 (en) 2016-06-28 2018-01-04 Northeast Ohio Medical University Compositions and methods for preventing bone loss and/or stimulating bone healing

Also Published As

Publication number Publication date
EP4114831A1 (en) 2023-01-11
KR20230022829A (ko) 2023-02-16
WO2021178420A1 (en) 2021-09-10
IL296137A (en) 2022-11-01
TW202146398A (zh) 2021-12-16
JP2023517539A (ja) 2023-04-26
AU2021231765A1 (en) 2022-10-06
MX2022010957A (es) 2023-01-24
CA3170415A1 (en) 2021-09-10
CN116157392A (zh) 2023-05-23

Similar Documents

Publication Publication Date Title
BR112018015419A2 (pt) degradantes seletivos de receptor de estrogênio e os usos dos mesmos
BR112022018706A2 (pt) Compostos de oxoisoindolina substituída para tratamento de câncer
BR122021005860A8 (pt) Derivados de aminoácidos e composição que os compreende
BR112018015413A2 (pt) inibidores de indoleamina-2,3-dioxigenase (ido)
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
BR112013020996A2 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
BR112023003580A2 (pt) Compostos heterocíclicos
BRPI0508102A (pt) inibidores de caspase e usos dos mesmos
BR112021011325A2 (pt) Derivados de rapamicina
BR112022003357A2 (pt) Compostos heterocíclicos
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
BR112021026899A2 (pt) Compostos heterocíclicos
BR112022010441A2 (pt) Análogos de equinocandina e método de preparação para os mesmos
BR112015007879A2 (pt) inibidores do vírus da hepatite c
BR112023023527A2 (pt) Inibidores de nlrp3
BR112015024109A2 (pt) derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp)
BR112022017574A2 (pt) Compostos que têm como alvo proteínas de ligação ao rna ou proteínas modificadoras de rna
BR112019023130A2 (pt) Compostos e métodos para tratamento de infecções bacterianas
BR112022012737A2 (pt) Composto antagonista de pd-l1

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: REDONA THERAPEUTICS, INC. (US)